U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy Pharmaceutical Investing
Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis Pharmaceutical Investing
New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia Pharmaceutical Investing
BioHarvest Sciences Inc. Announces Live Quarterly Shareholder Update Event July 7, 2022, at 2:00 PM ET Life Science Investing
BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal Pharmaceutical Investing
New Survey Offers Perspective on Mental and Emotional Journey for Patients Diagnosed with Slow-Growing Blood Cancer Pharmaceutical Investing
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV Pharmaceutical Investing
Treatment With Hepcludex® Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks Pharmaceutical Investing
MAVIRET® Approved by Health Canada for Paediatric Patients with Chronic Hepatitis C Pharmaceutical Investing
